Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | ERN1 | O75460 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11872397 | 0.91 | TDP1 (0.67) | TDP1AHRERN1ALDH1A1 | |
| SCHEMBL1547171 | 0.86 | TDP1 (0.55) | TDP1ERN1KDM4EALDH1A1MAPT | |
| SCHEMBL8035343 | 0.84 | TDP1 (0.53) | TDP1AHRERN1HSD17B10KDM4E | |
| SCHEMBL5181460 | 0.84 | TDP1 (0.53) | TDP1ERN1ALOX5BACE1 | |
| SCHEMBL95435 | 0.82 | TDP1 (1.00) | TDP1ERN1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL29889164 | 0.82 | TDP1 (1.00) | TDP1ERN1HSD17B10KDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL8037724 | 0.80 | TDP1 (0.95) | TDP1ERN1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL5736354 | 0.80 | ALOX5 (0.59) | TDP1ERN1ALOX5 | |
| SCHEMBL4552823 | 0.80 | TDP1 (0.48) | TDP1ERN1HSD17B10ALOX5BACE1 | |
| SCHEMBL27535920 | 0.80 | TAAR1 (0.51) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150351401-A1 | SUBSTITUTED [1,2,4]TRIAZOLE AND IMIDAZOLE COMPOUNDS | BASF SE (DE) | 2015-12-10 | — | — | US | disclosed |
| EP-2935225-A1 | SUBSTITUTED [1,2,4]TRIAZOLE AND IMIDAZOLE COMPOUNDS | BASF SE (DE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095655-A1 | SUBSTITUTED [1,2,4]TRIAZOLE AND IMIDAZOLE COMPOUNDS | BASF SE (DE) | 2014-06-26 | — | — | WO | disclosed |
| US-8557828-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2500347-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | Abbott Laboratories (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2142552-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120041003-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2142552-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008134690-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041003-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | TDP1 1156/4885AHR 4215/4885ERN1 459/4885 |
| US-20150351401-A1 | SUBSTITUTED [1,2,4]TRIAZOLE AND IMIDAZOLE COMPOUNDS | CYP1B1, CYP4B1, COX4I1 | TDP1 1077/4885AHR 453/4885ERN1 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.